Table 1.
Clinical trials of hormonal therapy in recurrent endometrial cancer
| Reference | (n) | Treatment | RR | PFS | OS |
|---|---|---|---|---|---|
| Thigpen et al (GOG 81)12 | 154 | MPA 1,000 mg daily versus | 15 | 2.5 | 7 |
| 145 | MPA 200 mg daily | ||||
| Lentz et al (GOG 121)39 | 58 | MA 800 mg daily | 25 | 3.2 | 11.1 |
| Thigpen et al (GOG 81-F)20 | 68 | Tamoxifen 20 mg BID | 10 | 1.9 | 8.8 |
| Whitney et al (GOG 119)13 | 58 | MPA 100 mg BID on alternating weeks plus tamoxifen 20 mg daily continuous | 33 | 3 | 13 |
| Fiorica et al (GOG 153)40 | 56 | MA 80 mg BID ×3 weeks alternating with tamoxifen 20 mg BID ×3 weeks | 27 | 2.7 | 14 |
| Rose et al (GOG 168)28 | 23 | Anastrozole 1 mg daily | 9 | 1 | 6 |
| Ma et al29 | 32 | Letrozole 2.5 mg daily | 9.4 | 3.9 | 8.8 |
| Asbury et al24 | 40 | Goserelin acetate 3.6 mg monthly | 11 | 1.9 | 7.3 |
Abbreviations: MPA, medroxyprogesterone acetate; MA, megestrol acetate; PFS, progression-free survival; OS, overall survival; RR, response rate; GOG, Gynecologic Oncology Group; BID, twice daily.